191 related articles for article (PubMed ID: 17191752)
21. Efficacy and tolerability of high dose sublingual immunotherapy in patients with rhinoconjunctivitis.
Worm M
Eur Ann Allergy Clin Immunol; 2006 Dec; 38(10):355-60. PubMed ID: 17274520
[TBL] [Abstract][Full Text] [Related]
22. Safety of sublingual immunotherapy with a monomeric allergoid in very young children.
Agostinis F; Tellarini L; Canonica GW; Falagiani P; Passalacqua G
Allergy; 2005 Jan; 60(1):133. PubMed ID: 15575951
[No Abstract] [Full Text] [Related]
23. [Sublingual immunotherapy with allergenic extract of Dermatophagoides pteronyssinus in asthmatic children].
Rodríguez Santos O
Rev Alerg Mex; 2004; 51(5):177-80. PubMed ID: 15794407
[TBL] [Abstract][Full Text] [Related]
24. Adherence to sublingual immunotherapy in preschool children.
Pajno GB; Caminiti L; Crisafulli G; Barberi S; Landi M; Aversa T; Valenzise M; Passalacqua G
Pediatr Allergy Immunol; 2012 Nov; 23(7):688-9. PubMed ID: 22985448
[No Abstract] [Full Text] [Related]
25. Three years of specific immunotherapy may be sufficient in house dust mite respiratory allergy.
Tabar AI; Arroabarren E; Echechipía S; García BE; Martin S; Alvarez-Puebla MJ
J Allergy Clin Immunol; 2011 Jan; 127(1):57-63, 63.e1-3. PubMed ID: 21211641
[TBL] [Abstract][Full Text] [Related]
26. Safety and pharmacoeconomics of a cluster administration of mite immunotherapy compared to the traditional one.
Mauro M; Russello M; Alesina R; Sillano V; Alessandrini A; Dama A; Passalacqua G; Senna G
Eur Ann Allergy Clin Immunol; 2006 Jan; 38(1):31-4. PubMed ID: 16544586
[TBL] [Abstract][Full Text] [Related]
27. Quantitative assessment of the compliance with a once-daily sublingual immunotherapy regimen in real life (EASY Project: Evaluation of A novel SLIT formulation during a Year).
Passalacqua G; Musarra A; Pecora S; Amoroso S; Antonicelli L; Cadario G; Di Gioacchino M; Lombardi C; Ridolo E; Sacerdoti G; Schiavino D; Senna G
J Allergy Clin Immunol; 2006 Apr; 117(4):946-8. PubMed ID: 16630956
[No Abstract] [Full Text] [Related]
28. Double-blind, placebo-controlled evaluation of grass pollen specific immunotherapy with oral drops administered sublingually or supralingually.
Panzner P; Petrás M; Sýkora T; Lesná I
Respir Med; 2008 Sep; 102(9):1296-304. PubMed ID: 18585908
[TBL] [Abstract][Full Text] [Related]
29. [Allergy vaccination with only 4 injections per year].
Krankenpfl J; 2005; 43(7-10):261-2. PubMed ID: 16515332
[No Abstract] [Full Text] [Related]
30. Two year follow-up of immunological response in mite-allergic children treated with sublingual immunotherapy. Comparison with subcutaneous administration.
Antúnez C; Mayorga C; Corzo JL; Jurado A; Torres MJ
Pediatr Allergy Immunol; 2008 May; 19(3):210-8. PubMed ID: 18399897
[TBL] [Abstract][Full Text] [Related]
31. A model for management of sublingual immunotherapy.
Frati F; Sensi L; Di Rienzo V; Senna GE; Incorvaia C; Marcucci F
Eur Ann Allergy Clin Immunol; 2003 Feb; 35(2):56-60. PubMed ID: 12674040
[TBL] [Abstract][Full Text] [Related]
32. [Desensitization -- at home and without pricks. How effective is sublingual immunotherapy? Interview by Erik Heintz].
Darsow U
MMW Fortschr Med; 2005 Aug; 147(33-34):15. PubMed ID: 16144088
[No Abstract] [Full Text] [Related]
33. Sublingual immunotherapy: administration, dosages, use.
Frati F; La Grutta S; Bernardini R; Zampogna S; Scurati S; Puccinelli P; Riario-Sforza GG; Incorvaia C
Int J Immunopathol Pharmacol; 2009; 22(4 Suppl):13-6. PubMed ID: 19944004
[TBL] [Abstract][Full Text] [Related]
34. Safety of cluster specific immunotherapy with a modified high-dose house dust mite extract.
Nieto García A; Nevot Falcó S; Carrillo Díaz T; Cumplido Bonny JA; Izquierdo Calderón JP; Hernández-Peña J
Eur Ann Allergy Clin Immunol; 2013 May; 45(3):78-83. PubMed ID: 23862396
[TBL] [Abstract][Full Text] [Related]
35. Children passive smoking jeopardises the efficacy of standard anti-allergic pharmacological therapy, while sublingual immunotherapy withstands.
Marogna M; Massolo A; Colombo F; Isella P; Bruno M; Falagiani P
Allergol Immunopathol (Madr); 2011; 39(2):60-7. PubMed ID: 21216083
[TBL] [Abstract][Full Text] [Related]
36. Safety of specific sublingual immunotherapy with SQ standardized grass allergen tablets in children.
Ibañez MD; Kaiser F; Knecht R; Armentia A; Schöpfer H; Tholstrup B; Bufe A
Pediatr Allergy Immunol; 2007 Sep; 18(6):516-22. PubMed ID: 17680910
[TBL] [Abstract][Full Text] [Related]
37. Sublingual immunotherapy and subcutaneous immunotherapy: issues in the United States.
Greenberger PA; Ballow M; Casale TB; Platts-Mills TA; Sampson HA
J Allergy Clin Immunol; 2007 Dec; 120(6):1466-8. PubMed ID: 17936891
[No Abstract] [Full Text] [Related]
38. The safety of sublingual immunotherapy with one or more allergens in adults.
Lombardi C; Gargioni S; Cottini M; Canonica GW; Passalacqua G
Allergy; 2008 Mar; 63(3):375-6. PubMed ID: 18269680
[No Abstract] [Full Text] [Related]
39. Anaphylaxis caused by allergen sublingual immunotherapy?
André C; Fadel R
Allergy; 2007 Oct; 62(10):1220-1. PubMed ID: 17845597
[No Abstract] [Full Text] [Related]
40. Sublingual immunotherapy with natural rubber latex: a case report with 8-year follow-up.
Pecora V; Aruanno A; Buonuomo A; De Pasquale T; Colagiovanni A; Sabato V; Rizzi A; Pascolini L; Ricci AG; Patriarca G; Nucera E; Schiavino D
Contact Dermatitis; 2010 Jul; 63(1):53-4. PubMed ID: 20597936
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
